This inventor holds 2 USPTO granted patents. Top assignee: Cyclacel Limited. Active years: 2001-2003.
Location History:
- Oxford, GB (2001)
- Summertown, GB (2003)
Company Filing History:
Years Active: 2001-2003
Title: Lynne Suzanne Cox: Innovator in PCNA Binding Substances
Introduction
Lynne Suzanne Cox is a prominent inventor based in Oxford, GB. She has made significant contributions to the field of biochemistry, particularly in the development of substances that bind to Proliferating Cell Nuclear Antigen (PCNA). With a total of 2 patents, her work has implications for treating various hyperproliferative disorders, including cancer and psoriasis.
Latest Patents
One of Lynne's latest patents focuses on the identification of the P21WaF1-PCNA interaction site and its therapeutic applications. The patent discloses substances that possess the ability to bind to PCNA, which includes a fragment of the p21 protein comprising residues 141 to 160 of the amino acid sequence, or an active portion or derivative thereof. The critical sequence motif for PCNA binding is identified as OTSMTDFY, with specific residues highlighted as essential for this interaction. These innovative substances are designed to inactivate PCNA or functionally deplete its levels, providing a potential therapeutic avenue for disorders where PCNA is implicated.
Career Highlights
Lynne is currently associated with Cyclacel Limited, where she continues her research and development efforts. Her work has been instrumental in advancing the understanding of PCNA's role in cell proliferation and its potential as a therapeutic target.
Collaborations
Lynne has collaborated with notable colleagues, including Emma Warbrick and David Moore Glover, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Lynne Suzanne Cox's contributions to the field of biochemistry, particularly through her patents related to PCNA binding substances, highlight her role as a leading inventor. Her work not only advances scientific knowledge but also opens new avenues for therapeutic interventions in serious health conditions.